The Lancet Gastroenterology & Hepatology
Study
May 2024
Patients and professionals
A large UK-led trial of 386 newly diagnosed adults. Starting straight away with infliximab plus an immunosuppressant ('top-down') kept 79% in remission without steroids or surgery for a year, compared with 15% using the usual 'step-up' approach of trying milder drugs first. There were also fewer flares, serious side effects and operations. A blood test meant to predict who needed strong treatment did not help. Free to read in full.
Topics
Biologics and newer medicines
Research
About Crohn's disease
Jargon explained
top-down treatment
step-up treatment
biomarker
steroid-free remission
top-down
step-up
immunomodulator
randomised controlled trial
Frontline Gastroenterology (via PMC)
Guide
Nov 2025
For professionals
A readable summary of what the 2025 BSG guideline says about Crohn's. Key points: early 'top-down' infliximab with an immunomodulator for moderate to severe disease; avoiding long or repeated steroid courses; no longer suggesting immunomodulators alone; upadacitinib and risankizumab added; vedolizumab no longer routinely suggested; drug-level testing for anti-TNFs; early surgery as an option for limited ileocaecal disease; and offering early treatment after resection.
Topics
Medicines
Surgery
Monitoring
Jargon explained
top-down
step-up
therapeutic drug monitoring
ileocaecal resection
Rutgeerts score
immunogenicity
The Lancet Gastroenterology & Hepatology
Study
Nov 2026
For professionals
Five-year follow-up of the PROFILE trial. People who had early top-down treatment were less likely to be admitted to hospital or to develop strictures or fistulas than those treated step-up, with no difference seen in serious infections or cancers, suggesting early treatment may change the course of the disease.
Topics
Biologics and newer medicines
Research
Jargon explained
top-down
step-up
disease modification
stricturing
penetrating disease
The Lancet
Study
Feb 2015
For professionals
A trial of how to stop Crohn's returning after bowel surgery. Treating people according to their risk, checking with a colonoscopy at six months and stepping up treatment if the disease had come back worked better than standard drug treatment alone. It also showed that even low-risk patients need monitoring.
Topics
Surgery
Monitoring
Research
Jargon explained
post-operative recurrence
colonoscopy
step-up
resection
The Lancet
Study
Dec 2017
Patients and professionals
CALM compared deciding treatment on symptoms alone with 'tight control', where treatment was stepped up if blood or poo tests (CRP and faecal calprotectin) showed inflammation even when people felt fine. After 48 weeks, 46% in the tight control group had a healed bowel lining compared with 30% in the symptom-only group. It is a cornerstone of the 'treat to target' approach.
Topics
Monitoring
Biologics and newer medicines
Research
Jargon explained
tight control
faecal calprotectin
CRP
mucosal healing
treat to target
Cochrane (via PMC)
Systematic review
Aug 2020
Patients and professionals
A Cochrane review suggesting that stepping up treatment based on a colonoscopy after surgery may reduce Crohn's coming back compared with waiting for symptoms. Whether to start treatment immediately after surgery or only after a colonoscopy remains uncertain.
Topics
Surgery
Monitoring
Research
Jargon explained
post-operative recurrence
colonoscopy
prophylaxis
Gastroenterology
Guideline
Apr 2021
For professionals
An international expert agreement on what 'treat to target' should aim for in IBD. Short-term goals are feeling better and getting blood and poo inflammation tests back to normal. Long-term goals include a healed bowel lining seen at endoscopy, no disability, a normal quality of life, and normal growth in children. Healing through the full bowel wall in Crohn's is not yet a formal target but is a sign of deeper remission.
Topics
Monitoring
Research
Medicines
Jargon explained
treat to target
endoscopic healing
transmural healing
biomarker
calprotectin
CRP
clinical remission
NHS
Web page
Apr 2026
For patients
Explains piles: lumps in and around the anus that commonly cause bright red blood after a poo, itching, mucus on the paper and a feeling of not having finished. Lists self-care steps, what a pharmacist can offer and hospital treatments such as banding. Says to get an urgent GP appointment or use 111 if you have piles with painless bleeding, a high temperature or pus leaking.
Topics
Bleeding from the bottom
Around the bottom (perianal)
Symptoms
Jargon explained
haemorrhoids
rubber band ligation
sclerotherapy
laxatives
European Crohn's and Colitis Organisation (J Crohns Colitis)
Guideline
Oct 2024
For professionals
Europe's main expert guideline on which medicines to use for Crohn's disease, published as the first of a two-part set (the second covers surgery). It weighs up the trial evidence for steroids, immunosuppressants, biologics and newer tablets, including treatment of disease around the back passage. UK specialists use it alongside the BSG guideline.
Topics
Medicines
Biologics and newer medicines
Immunosuppressants
Around the bottom (perianal)
Jargon explained
biologic
immunomodulator
induction
maintenance
de-escalation
perianal fistula
GRADE
Journal of Crohn's and Colitis via PubMed Central
Systematic review
Feb 2020
For professionals
Reviews the evidence for 'treat to target', where treatment is adjusted not just to symptoms but to measured goals such as a healed bowel lining and normal blood or poo markers. It explains the idea behind the STRIDE targets and notes that firm proof that aiming for healing improves long-term outcomes was still emerging.
Topics
Monitoring
Research
Jargon explained
treat to target
mucosal healing
biomarker
STRIDE
Crohn's & Colitis UK
Guide
Jul 2023
For patients
An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.
Topics
Biologics and newer medicines
Medicines
Jargon explained
biologic
biosimilar
anti-TNF
IL-23 inhibitor
JAK inhibitor
advanced therapy
Crohn's & Colitis UK
Web page
Aug 2023
For patients
A practical to-do list for the weeks after a diagnosis of Crohn's, ulcerative colitis or microscopic colitis. It explains the term IBD and points people to support and information to help them get started living with the condition.
Topics
About Crohn's disease
Living well
Jargon explained
inflammatory bowel disease